Pfizer has received marketing authorisation for its drug Lorviqua (lorlarinib) from the European Commission (EC).
The drug is a monotherapy for treatment of adults diagnosed with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC), who have no received prior treatment with an ALK inhibitor.
Lorviqua
